McAdam LLC’s Neuronetics STIM Stock Holding History

McAdam LLC’s Portfolio STIM Stock Details STIM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-50,791	Closed	-$187K	–	387
2025 Q1	$187K	Buy	+50,791	New	+$185K	0.01%	330

Other funds holding STIM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

MCM

Masters Capital Management Atlanta, Georgia $3.9B AUM 50.88% 1-Year Est. Return

MHP

Manatuck Hill Partners Westport, Connecticut $302M AUM 117.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return

McAdam LLC's STIM Position: Q2 2025 in Review

McAdam LLC sold out of Neuronetics (STIM) in Q2 2025, closing a stake of 50,791 shares — an estimated $187K sold.

McAdam LLC first reported a position in STIM in Q1 2025 and held it in 1 quarter. The position peaked at $187K in Q1 2025. 90 funds tracked by Wall St. Rank hold STIM as of Q2 2025.

McAdam LLC reported no remaining Neuronetics position as of Q2 2025 after selling out during the quarter.
McAdam LLC sold 50,791 Neuronetics shares in Q2 2025, an estimated $187K.
McAdam LLC first reported a position in Neuronetics in Q1 2025 and held it in 1 quarter.
McAdam LLC's Neuronetics position peaked at $187K in Q1 2025.
90 funds tracked by Wall St. Rank held Neuronetics as of Q2 2025.

Based on McAdam LLC's 13F filing for Q2 2025, filed 15 Jul 2025.